The name of the experimental drug was heard so frequently in hotel hallways at the conference that it sounded like an incantation: aducanumab, aducanumab, aducanumab.
Regardless of the eventual FDA verdict on Biogen’s once-bagged, now-revived anti-amyloid antibody, data from clinical trials of the treatment have inarguably altered the course of drug discovery and development for Alzheimer’s disease.
That was the message delivered by San Diego’s Paul Aisen, an industry veteran and head of the University of Southern California’s Alzheimer’s Therapeutic Research Institute, speaking Friday at the Clinical Trials on Alzheimer’s Disease congress.
The Biogen (NASDAQ: BIIB) announcement in October… Read more »
UNDERWRITERS AND PARTNERS
